Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HUMATIN vs AMIKACIN SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and production of nonfunctional proteins.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.
Hepatic coma (adjunctive therapy to reduce ammonia-forming bacteria in the gut),Diarrhea caused by enteropathogenic bacteria (e.g., Shigella, E. coli, Salmonella, Proteus, Staphylococcus, Pseudomonas aeruginosa)
FDA-approved: Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus) when other antibiotics are ineffective or contraindicated.,Off-label: Used in combination for enterococcal endocarditis, mycobacterial infections (e.g., tuberculosis), and severe neonatal sepsis.
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
Terminal: 2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; neonates 4-8 hours.
Minimally absorbed from the gastrointestinal tract; systemically absorbed drug undergoes minimal hepatic metabolism.
Amikacin is not significantly metabolized; it is excreted unchanged primarily by glomerular filtration. Minimal hepatic metabolism.
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Renal: >90% unchanged via glomerular filtration. Biliary/fecal: <1%.
0% (negligible binding due to high polarity and minimal absorption)
0-11% (low binding to albumin).
0.2 L/kg (reflects limited distribution to extracellular fluid in absorbed fraction; primarily confined to GI tract)
0.25-0.4 L/kg; approximates extracellular fluid volume; increased in edema, decreased in dehydration.
Oral: ~1% (ranges 0.5-1.5% due to poor absorption from gastrointestinal tract)
IM: nearly 100% (rapid and complete).
Reduce dose and/or extend interval based on Cr Cl: Cr Cl 50-90 m L/min: 60-90% of dose; Cr Cl 10-50 m L/min: 30-60% of dose; Cr Cl <10 m L/min: 20-30% of dose.
Cr Cl 20-50 m L/min: 7.5 mg/kg every 24 hours; Cr Cl 10-20 m L/min: 7.5 mg/kg every 48 hours; Cr Cl <10 m L/min: 7.5 mg/kg every 72-96 hours; hemodialysis: 7.5 mg/kg post-dialysis with monitoring.
No specific Child-Pugh based adjustments; caution in severe hepatic impairment due to potential nephrotoxicity.
No dose adjustment required for hepatic impairment; monitor drug levels if severe dysfunction.
For hepatic coma: 15-25 mg/kg/day orally in 4 divided doses; for infectious diarrhea: 50 mg/kg/day orally in 4 divided doses, max 4 g/day.
Neonates <7 days: 15-20 mg/kg IV every 24-48 hours; neonates 7-28 days: 15 mg/kg every 24 hours; infants/children: 15-22.5 mg/kg/day divided every 8-12 hours; maximum 1.5 g/day.
Adjust based on renal function; monitor for nephrotoxicity and ototoxicity; consider lower initial doses due to age-related renal decline.
Reduce initial dose based on renal function; usual dose 7.5 mg/kg every 24-48 hours with close monitoring of serum creatinine and drug levels due to age-related decreased GFR.
No FDA black box warning.
WARNING: Amikacin can cause neurotoxicity, ototoxicity, and nephrotoxicity. The risk of nephrotoxicity is greater in patients with impaired renal function and those receiving high doses or prolonged therapy. Ototoxicity may be irreversible and can occur even after drug discontinuation. Monitor renal function and drug levels closely.
Ototoxicity (mainly with prolonged use or renal impairment),Nephrotoxicity,Neuromuscular blockade (use caution in patients with myasthenia gravis or receiving neuromuscular blocking agents),Superinfection with resistant organisms,Use in renal impairment may increase risk of toxicity,Not for systemic infections (poor absorption)
Nephrotoxicity: Risk increased with advanced age, pre-existing renal impairment, concomitant use of other nephrotoxic drugs (e.g., amphotericin B, cyclosporine, NSAIDs).,Ototoxicity: Can cause irreversible bilateral hearing loss, tinnitus, and vestibular damage. Monitor audiometry in patients with risk factors.,Neuromuscular blockade: May exacerbate weakness in patients with neuromuscular disorders (e.g., myasthenia gravis, Parkinsonism). Use with caution during anesthesia or with neuromuscular blocking agents.,Hypersensitivity reactions: Including rash, drug fever, and anaphylaxis.,Superinfection: Prolonged use may lead to overgrowth of nonsusceptible organisms.,Pregnancy: Risk of fetal harm (ototoxicity) if administered during pregnancy.
Hypersensitivity to paromomycin or other aminoglycosides,Intestinal obstruction,Severe ulcerative bowel lesions
Hypersensitivity to amikacin, other aminoglycosides, or any component of the formulation.,Preexisting severe renal impairment (unless life-threatening infection and no alternative).,Concurrent use of other nephrotoxic or ototoxic drugs (relative contraindication).,Myasthenia gravis (caution; neuromuscular blocking effect).
No significant food interactions. Administer with meals to minimize gastrointestinal irritation.
No significant food interactions. Avoid alcohol as it may increase side effects like dizziness.
FDA Pregnancy Category D. Humatin (paromomycin) is an aminoglycoside antibiotic. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans. However, potential benefits may warrant use in pregnant women despite potential risks. Aminoglycosides can cause fetal harm when administered to a pregnant woman, including ototoxicity and nephrotoxicity. Paromomycin is poorly absorbed after oral administration, so systemic exposure is minimal. Risk is considered low, but caution is advised.
Aminoglycosides including amikacin have been associated with fetal ototoxicity and nephrotoxicity when administered during pregnancy. There is a potential for eighth cranial nerve damage and renal impairment in the fetus, particularly during the second and third trimesters. Animal studies have shown evidence of harm, but controlled human studies are lacking. Use only if clearly needed and if safer alternatives are unavailable.
It is not known whether paromomycin is excreted in human milk after oral administration. Paromomycin is minimally absorbed systemically, so exposure to breastfed infants is expected to be low. However, because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio: Not available.
Amikacin is excreted into human milk in low concentrations. The milk-to-plasma ratio is approximately 0.1–0.2. Due to low oral bioavailability from the gastrointestinal tract, systemic effects in the breastfed infant are unlikely. However, caution is advised due to the potential for altered infant gut flora and direct mucosal irritation. Use only if benefits outweigh risks.
No dose adjustment is required during pregnancy. Paromomycin is poorly absorbed orally, and its pharmacokinetics are not significantly altered in pregnancy. However, caution is advised in patients with renal impairment or inflammatory bowel disease due to potential increased absorption.
Pregnancy does not typically require dosing adjustments for amikacin. However, due to increased glomerular filtration rate during pregnancy, levels may be lower; monitor drug concentrations and adjust doses to achieve therapeutic range. Standard dosing based on ideal body weight and renal function should be followed.
Humatin (paromomycin) is an aminoglycoside antibiotic used primarily for intestinal amebiasis and hepatic coma. For hepatic coma, use as short-term adjunctive therapy; monitor for ototoxicity and nephrotoxicity, especially in renal impairment. Oral absorption is poor, so systemic toxicity is rare except with ulcerative bowel disease. Administer with food to reduce GI upset.
Monitor peak (15-30 mcg/m L) and trough (<5 mcg/m L) levels to avoid nephrotoxicity and ototoxicity. Adjust dose in renal impairment using Cr Cl. Synergy with beta-lactams for Gram-negative infections. Avoid concurrent loop diuretics.
Take this medication exactly as prescribed, with food to lessen stomach upset.,Complete the full course of therapy even if you feel better.,Drink plenty of fluids to maintain hydration.,Report any hearing loss, ringing in ears, dizziness, or changes in urine output immediately.,May cause diarrhea; notify your doctor if severe or persistent.
Take exactly as prescribed; do not skip doses or stop early.,Report any hearing loss, tinnitus, dizziness, or vertigo immediately.,Drink plenty of fluids to maintain hydration, unless contraindicated.,Avoid taking other medications without consulting your doctor, especially water pills or other antibiotics.
No interactions on record
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HUMATIN vs AMIKACIN SULFATE, answered by our medical review team.
HUMATIN is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and production of nonfunctional proteins.. AMIKACIN SULFATE is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis. Also disrupts bacterial cell membrane integrity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HUMATIN and AMIKACIN SULFATE depend on the specific clinical indication. These are both Aminoglycoside Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HUMATIN is: 15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.. The standard adult dose of AMIKACIN SULFATE is: 15 mg/kg/day IV or IM divided every 8-12 hours; typical adult dose 500 mg IV/IM every 12 hours or 7.5 mg/kg every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HUMATIN and AMIKACIN SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HUMATIN is classified as Category C. FDA Pregnancy Category D. Humatin (paromomycin) is an aminoglycoside antibiotic. There is positive evidence of human fetal risk based on adverse reaction data from investigational . AMIKACIN SULFATE is classified as Category D/X. Aminoglycosides including amikacin have been associated with fetal ototoxicity and nephrotoxicity when administered during pregnancy. There is a potential for eighth cranial nerve . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.